BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 25892475)

  • 21. Value of anti-modified citrullinated vimentin and third-generation anti-cyclic citrullinated peptide compared with second-generation anti-cyclic citrullinated peptide and rheumatoid factor in predicting disease outcome in undifferentiated arthritis and rheumatoid arthritis.
    van der Linden MP; van der Woude D; Ioan-Facsinay A; Levarht EW; Stoeken-Rijsbergen G; Huizinga TW; Toes RE; van der Helm-van Mil AH
    Arthritis Rheum; 2009 Aug; 60(8):2232-41. PubMed ID: 19644872
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fine specificity of anti-citrullinated peptide antibodies discloses a heterogeneous antibody population in rheumatoid arthritis.
    Goules JD; Goules AV; Tzioufas AG
    Clin Exp Immunol; 2013 Oct; 174(1):10-7. PubMed ID: 23711220
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The fibrin-derived citrullinated peptide β60-74Cit₆₀,₇₂,₇₄ bears the major ACPA epitope recognised by the rheumatoid arthritis-specific anticitrullinated fibrinogen autoantibodies and anti-CCP2 antibodies.
    Cornillet M; Sebbag M; Verrouil E; Magyar A; Babos F; Ruyssen-Witrand A; Hudecz F; Cantagrel A; Serre G; Nogueira L
    Ann Rheum Dis; 2014 Jun; 73(6):1246-52. PubMed ID: 23636655
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antibodies to a new viral citrullinated peptide, VCP2: fine specificity and correlation with anti-cyclic citrullinated peptide (CCP) and anti-VCP1 antibodies.
    Pratesi F; Tommasi C; Anzilotti C; Puxeddu I; Sardano E; Di Colo G; Migliorini P
    Clin Exp Immunol; 2011 Jun; 164(3):337-45. PubMed ID: 21413944
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Shared immunological targets in the lungs and joints of patients with rheumatoid arthritis: identification and validation.
    Ytterberg AJ; Joshua V; Reynisdottir G; Tarasova NK; Rutishauser D; Ossipova E; Haj Hensvold A; Eklund A; Sköld CM; Grunewald J; Malmström V; Jakobsson PJ; Rönnelid J; Padyukov L; Zubarev RA; Klareskog L; Catrina AI
    Ann Rheum Dis; 2015 Sep; 74(9):1772-7. PubMed ID: 24817415
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Anti-citrullinated peptides as autoantigens in rheumatoid arthritis-relevance to treatment.
    Sakkas LI; Bogdanos DP; Katsiari C; Platsoucas CD
    Autoimmun Rev; 2014 Nov; 13(11):1114-20. PubMed ID: 25182207
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Are there autoantibodies reacting against citrullinated peptides derived from type I and type II collagens in patients with rheumatoid arthritis?
    Koivula MK; Aman S; Karjalainen A; Hakala M; Risteli J
    Ann Rheum Dis; 2005 Oct; 64(10):1443-50. PubMed ID: 16162901
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Different Hierarchies of Anti-Modified Protein Autoantibody Reactivities in Rheumatoid Arthritis.
    Sahlström P; Hansson M; Steen J; Amara K; Titcombe PJ; Forsström B; Stålesen R; Israelsson L; Piccoli L; Lundberg K; Klareskog L; Mueller DL; Catrina AI; Skriner K; Malmström V; Grönwall C
    Arthritis Rheumatol; 2020 Oct; 72(10):1643-1657. PubMed ID: 32501655
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Associations with smoking and shared epitope differ between IgA- and IgG-class antibodies to cyclic citrullinated peptides in early rheumatoid arthritis.
    Svärd A; Skogh T; Alfredsson L; Ilar A; Klareskog L; Bengtsson C; Kastbom A
    Arthritis Rheumatol; 2015 May; 67(8):2032-7. PubMed ID: 25916813
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antibody responses to de novo identified citrullinated fibrinogen peptides in rheumatoid arthritis and visualization of the corresponding B cells.
    Joshua V; Schobers L; Titcombe PJ; Israelsson L; Rönnelid J; Hansson M; Catrina AI; Pruijn GJ; Malmström V
    Arthritis Res Ther; 2016 Dec; 18(1):284. PubMed ID: 27906052
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Identification of citrullinated vimentin peptides as T cell epitopes in HLA-DR4-positive patients with rheumatoid arthritis.
    Feitsma AL; van der Voort EI; Franken KL; el Bannoudi H; Elferink BG; Drijfhout JW; Huizinga TW; de Vries RR; Toes RE; Ioan-Facsinay A
    Arthritis Rheum; 2010 Jan; 62(1):117-25. PubMed ID: 20039411
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Identification of potential autoantigens in anti-CCP-positive and anti-CCP-negative rheumatoid arthritis using citrulline-specific protein arrays.
    Poulsen TBG; Damgaard D; Jørgensen MM; Senolt L; Blackburn JM; Nielsen CH; Stensballe A
    Sci Rep; 2021 Aug; 11(1):17300. PubMed ID: 34453079
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pathogenic Citrulline-Multispecific B Cell Receptor Clades in Rheumatoid Arthritis.
    Titcombe PJ; Wigerblad G; Sippl N; Zhang N; Shmagel AK; Sahlström P; Zhang Y; Barsness LO; Ghodke-Puranik Y; Baharpoor A; Hansson M; Israelsson L; Skriner K; Niewold TB; Klareskog L; Svensson CI; Amara K; Malmström V; Mueller DL
    Arthritis Rheumatol; 2018 Dec; 70(12):1933-1945. PubMed ID: 29927106
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The ACPA recognition profile and subgrouping of ACPA-positive RA patients.
    Willemze A; Böhringer S; Knevel R; Levarht EW; Stoeken-Rijsbergen G; Houwing-Duistermaat JJ; van der Helm-van Mil AH; Huizinga TW; Toes RE; Trouw LA
    Ann Rheum Dis; 2012 Feb; 71(2):268-74. PubMed ID: 21998120
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antibodies to citrullinated alpha-enolase peptide 1 are specific for rheumatoid arthritis and cross-react with bacterial enolase.
    Lundberg K; Kinloch A; Fisher BA; Wegner N; Wait R; Charles P; Mikuls TR; Venables PJ
    Arthritis Rheum; 2008 Oct; 58(10):3009-19. PubMed ID: 18821669
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antibodies to citrullinated proteins and differences in clinical progression of rheumatoid arthritis.
    van der Helm-van Mil AH; Verpoort KN; Breedveld FC; Toes RE; Huizinga TW
    Arthritis Res Ther; 2005; 7(5):R949-58. PubMed ID: 16207336
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Diagnostic value of anti-mutated citrullinated vimentin in comparison to anti-cyclic citrullinated peptide and anti-viral citrullinated peptide 2 antibodies in rheumatoid arthritis: an Italian multicentric study and review of the literature.
    Bartoloni E; Alunno A; Bistoni O; Bizzaro N; Migliorini P; Morozzi G; Doria A; Mathieu A; Lotzniker M; Allegri F; Riccieri V; Alpini C; Gabrielli A; Tampoia M; Gerli R;
    Autoimmun Rev; 2012 Sep; 11(11):815-20. PubMed ID: 22394488
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The anti-mutated citrullinated vimentin response classifies patients with rheumatoid arthritis into broad and narrow responders.
    Engelmann R; Brandt J; Eggert M; Karberg K; Krause A; Neeck G; Mueller-Hilke B
    J Rheumatol; 2009 Dec; 36(12):2670-4. PubMed ID: 19884278
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Persistence of Disease-Associated Anti-Citrullinated Protein Antibody-Expressing Memory B Cells in Rheumatoid Arthritis in Clinical Remission.
    Pelzek AJ; Grönwall C; Rosenthal P; Greenberg JD; McGeachy M; Moreland L; Rigby WFC; Silverman GJ
    Arthritis Rheumatol; 2017 Jun; 69(6):1176-1186. PubMed ID: 28118534
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The HLA-DRB1 shared epitope alleles are primarily a risk factor for anti-cyclic citrullinated peptide antibodies and are not an independent risk factor for development of rheumatoid arthritis.
    van der Helm-van Mil AH; Verpoort KN; Breedveld FC; Huizinga TW; Toes RE; de Vries RR
    Arthritis Rheum; 2006 Apr; 54(4):1117-21. PubMed ID: 16572446
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.